Decitabine + Cedazuridine bulk supplier for pharma manufacturers

Decitabine + Cedazuridine 35 mg + 100mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 35 mg + 100mg

Reference Brands: Inqovi (USA/EU)

Decitabine/cedazuridine is an oral fixed-dose combination used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Cedazuridine improves oral absorption of decitabine by inhibiting its breakdown, allowing patients to receive effective decitabine therapy without injections.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Decitabine + Cedazuridine? List it or send an offer →

Product Description:

This fixed-dose combination solves a pharmacological problem rather than a biological one. Decitabine given by mouth is destroyed almost entirely by cytidine deaminase in the gut and liver, so it has always required intravenous administration over five consecutive days. Cedazuridine inhibits that enzyme, allowing an oral decitabine dose to reach systemic exposure equivalent to the standard infusion.

The indication is myelodysplastic syndromes, including chronic myelomonocytic leukaemia, across the full risk spectrum. Efficacy and toxicity mirror the intravenous product, since the active drug and its exposure are the same: myelosuppression, febrile neutropenia, fatigue and nausea. The practical gain is that patients — typically elderly, often frail — avoid five infusion-centre visits every month, which changes what treatment is feasible in areas with limited day-unit capacity. Tablets must be taken on an empty stomach and never crushed or split.

Sourcing notes. Originator product, on patent, approved in a limited set of territories. Pricing is positioned against the cost of five days of infusion capacity rather than against generic injectable decitabine, which is a point worth making in tender discussions. Oral cytotoxic handling; room temperature storage.

How Decitabine + Cedazuridine is supplied today, and licensing ahead of patent expiry

Decitabine + Cedazuridine is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Decitabine + Cedazuridine, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Decitabine + Cedazuridine supply →

Back to Listing

Frequently Asked Questions

Decitabine + Cedazuridine is used for treating myelodysplastic syndromes and chronic myelomonocytic leukemia. Decitabine provides hypomethylating activity, while cedazuridine increases its oral absorption by inhibiting cytidine deaminase, allowing decitabine to achieve therapeutic systemic levels through an oral dosage.

Decitabine + Cedazuridine is made from two active components: decitabine, a DNA hypomethylating agent, and cedazuridine, an inhibitor of cytidine deaminase. Together, they enable effective oral administration of decitabine.

The trade name is Inqovi.

Inqovi is manufactured by Taiho Oncology and Astex Pharmaceuticals.

The generic name is decitabine and cedazuridine.

The brand name is Inqovi.

Decitabine + Cedazuridine is manufactured in the United States and Canada under Taiho and Astex production facilities for regulated markets.

Inqovi (Decitabine + Cedazuridine) is developed and sold by Taiho Oncology (Otsuka). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.